Gaorong Capital and CTS Capital led a more than CNY500m (~USD74m) Series C for Intellective Biologics (Zhixiang Bio), a China-based contract development and manufacturing organization that focuses on macromolecular biopharma process development, with follow-on from Fuho Capital, CNCB Investment Limited, Founder Securities, Win Harbor Capital and others.Read more